These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 26385534)
1. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534 [TBL] [Abstract][Full Text] [Related]
2. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy. Fonge H; Lee H; Reilly RM; Allen C Mol Pharm; 2010 Feb; 7(1):177-86. PubMed ID: 19924993 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Chen P; Cameron R; Wang J; Vallis KA; Reilly RM J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194 [TBL] [Abstract][Full Text] [Related]
4. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207 [TBL] [Abstract][Full Text] [Related]
5. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. Reilly RM; Kiarash R; Cameron RG; Porlier N; Sandhu J; Hill RP; Vallis K; Hendler A; Gariépy J J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315 [TBL] [Abstract][Full Text] [Related]
6. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates. Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962 [TBL] [Abstract][Full Text] [Related]
7. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer. Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376 [TBL] [Abstract][Full Text] [Related]
8. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF. Hu M; Scollard D; Chan C; Chen P; Vallis K; Reilly RM Nucl Med Biol; 2007 Nov; 34(8):887-96. PubMed ID: 17998090 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253 [TBL] [Abstract][Full Text] [Related]
10. Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375 [TBL] [Abstract][Full Text] [Related]
11. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. Cai Z; Chen Z; Bailey KE; Scollard DA; Reilly RM; Vallis KA J Nucl Med; 2008 Aug; 49(8):1353-61. PubMed ID: 18632822 [TBL] [Abstract][Full Text] [Related]
12. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy. Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [ Chan C; Fonge H; Lam K; Reilly RM Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737 [TBL] [Abstract][Full Text] [Related]
14. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548 [TBL] [Abstract][Full Text] [Related]
15. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu. Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157 [TBL] [Abstract][Full Text] [Related]
16. Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Wang J; Chen P; Su ZF; Vallis K; Sandhu J; Cameron R; Hendler A; Reilly RM Nucl Med Biol; 2001 Nov; 28(8):895-902. PubMed ID: 11711308 [TBL] [Abstract][Full Text] [Related]
18. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037 [TBL] [Abstract][Full Text] [Related]
19. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869 [TBL] [Abstract][Full Text] [Related]
20. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Ke S; Wen X; Gurfinkel M; Charnsangavej C; Wallace S; Sevick-Muraca EM; Li C Cancer Res; 2003 Nov; 63(22):7870-5. PubMed ID: 14633715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]